Pulse Biosciences Inc. (PLSE) is having a good Monday, and it's not hard to see why. The medical device company released clinical data from its nPulse Cardiac Catheter study on Friday, and investors are still digesting the implications. The results look solid, and the stock is responding accordingly.

Here's what makes this interesting: while the broader market is treading water with the Nasdaq down 0.14% and the S&P 500 down 0.05%, Pulse Biosciences shares are climbing. That's the hallmark of company-specific news overpowering general market sentiment, which is exactly what's happening here.

The Heart of the Matter: Clinical Data That Actually Delivers

On February 6, Pulse Biosciences unveiled clinical data from its first-in-human feasibility study of the nPulse Cardiac Catheter. The numbers tell a compelling story: 150 patients with atrial fibrillation were successfully treated, procedures were completed quickly, and adverse effects were minimal. For a medical device company, this is the trifecta you want to see.

The data was presented at the Annual AF Symposium 2026 in Boston, giving it the kind of visibility that gets the attention of both physicians and investors. The company isn't resting on these results either. They're gearing up to treat more patients as they launch a pivotal IDE study, which is the regulatory pathway toward broader commercialization.

The potential here is that nPulse could become a preferred option in the atrial fibrillation treatment market. That's a significant opportunity given how common the condition is and how doctors are always looking for treatments that combine effectiveness with safety.

Technical Picture Shows Strength with a Side of Caution

The stock's technical setup tells you everything about the recent momentum. Pulse Biosciences is currently trading 49% above its 20-day simple moving average and 39.4% above its 100-day SMA. Those are the kinds of numbers that indicate serious short-term strength.

Over the past year, shares are down 7.20%, but they're now sitting much closer to their 52-week highs than their lows. That suggests the stock has entered a recovery phase, which aligns with the positive clinical news.

Now for the caution: the RSI stands at 75.62, which puts the stock firmly in overbought territory. Meanwhile, the MACD is above its signal line, confirming bullish momentum. It's a mixed picture. The momentum is real, but the overbought reading suggests the stock might need to catch its breath before making another leg higher.

• Key Resistance: $24.50
• Key Support: $20.00

Momentum Score Confirms What the Chart Shows

According to market data, Pulse Biosciences scores a 68.22 on momentum metrics, earning it a "Strong" rating. That's quantitative confirmation that the stock is outperforming the broader market right now.

The Bottom Line: Pulse Biosciences is riding genuine momentum backed by solid clinical data. The strong momentum score reflects real performance, not just hype. That said, the overbought RSI reading means investors should keep their eyes open for any signs of a pullback or consolidation. Good news can only carry a stock so far before it needs to digest gains.

PLSE Price Action: Pulse Biosciences shares were up 4.05% at $21.59 during premarket trading on Monday.